Diabetes mellitus is a metabolic disorder resulting from impaired insulin secretion of pancreatic β-cells and disrupted insulin action in target organs (eg, liver, muscle, adipose tissue), followed by hyperglycemia and secretion or lack of action of endogenous insulin \[[@B1][@B2]\]. Diabetes mellitus is classified into two types, insulin-dependent (type-1) and ii) non-insulin-dependent (type-2). Type-1 diabetes currently accounts for roughly 5--10% of all cases of diabetes, however, its incidence is constantly increasing worldwide \[[@B3]\]. Type-1 diabetes primarily occurs in individuals who experience destruction of the insulin-secreting pancreatic β-cell by a genetic defect-induced chronic immune response, and its symptoms are caused by hyperglycemia resulting from insufficient function insulin \[[@B4][@B5][@B6]\]. Currently, it is considered that insulin supplementation is an essential therapy in type-1 diabetes \[[@B7]\]. One important challenge facing patients with diabetes is that lasting hyperglycemia increases the risk of kidney disease, heart disease, retinal injury, nerve damage, and vascular damage \[[@B8]\]. Therefore, it is necessary to establish suitable animal models for research investigating novel prevention and treatment approaches for diabetes mellitus.

Streptozotocin (2-deoxy-2-(3-methyl-3-nitrosourea)-1-D-glucopyranose), a naturally occurring compound produced by soil bacterial streptomyces achromogenes, is a highly selective cytotoxic reagent in the pancreatic β cells. It induces an inflammatory response of the insulin-producing β cells followed by insulitis and absolute insulin deficiency \[[@B9]\]. Based on these mechanisms, streptozotocin is widely used to induce experimental type-1 diabetic animal models \[[@B10][@B11][@B12]\]. Initially, it was administered at a high single dosage to induce complete death of pancreatic β cells within 2 days \[[@B13]\]. However, Like and Rossini noted that multiple challenges with low dose streptozotocin results in the slowly progressive type-1 diabetes and more closely resembles the clinical pathogenesis \[[@B14][@B15][@B16]\]; this approach is now widely used to establish type-1 diabetes in animals.

The National Institute of Food and Drug Safety Evaluation (NIFDS, Cheongju, Korea) has established its own animal strains to evaluate both efficacy and safety during new drug development. The objective of this study was to characterize the response of the C57BL/6N mice from the NIFDS treated with streptozotocin compared with that of other mice originating from the USA and Japan. In this study, multiple low dose treatments with streptozotocin were used to generate type-1 diabetic animal models which closely relate to clinical pathology. Thus, a study comparing well-established animal disease model using streptozotocin can provide insight into the validity and usefulness of NIFDS-derived mice in preclinical testing of antidiabetic substances and elucidating the mechanism of the progression of type-1 diabetes in humans.

Materials and Methods
=====================

Animals and treatment
---------------------

Male C57BL/6N mice were obtained from three different sources. C57BL/6NKorl were kindly provided by the Department of Laboratory Animal Resources in the National Institute of Food and Drug Safety Evaluation (NIFDS, Cheongju, Korea). The other two groups of C57BL/6N strain were purchased from different vendors located in the USA (referred C57BL/6NA) and Japan (referred C57BL/6NB). Animal protocol of this study was approved by the Institutional Animal Care and Use Committees at Pusan National University (PNU-2017-1632). Mice were acclimated to temperature (22±2) and humidity (55±5%)-controlled rooms with a 12 h light/dark cycle for seven days prior to use. They were randomly divided into two groups and the streptozotocin-treated group was given daily intraperitoneal injection with 50 mg/kg body weight of streptozotocin (Sigma, St. Louis, MO, USA) freshly dissolved in 0.1 M citrate buffer (pH 4.5) for 5 days. Body weight, water and food consumption were measured at least once a week after last dosing of streptozotocin. Liver and kidney tissues were harvested 4 weeks after the final administration.

Serum biochemical measurements
------------------------------

Serum sample was obtained from blood of each mouse using BD Microtainer Serum Collection Tube (BD Life Sciences, Franklin Lakes, NJ, USA). The sera were stored at −80℃ until the biochemical analyses. Serum glucose level was determined using commercial Glucose CII-test Wako (Wako Pure Chemical Industries, Ltd., Tokyo, Japan). Activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured using the protocol of Reitman and Frankel \[[@B17]\]. They were quantified spectrophotometrically using an MULTISKAN GO reader (Thermo Scientific, Waltham, MA, USA). The serum levels of total cholesterol, HDL-cholesterol, and LDL-cholesterol were determined by using an Automated Chemistry Analyzer (Prestige 24I, Tokyo Boeki Medical System, Tokyo, Japan).

Metabolites analysis in serum
-----------------------------

Metabolites in deproteinized serum were derivatized with O-phthalaldehyde/2-mercaptoethanol and quantified by HPLC with fluorescence detection (FLD-3100: Thermo Scientific, Waltham, MA, USA) on a HECTOR-T C18 column (3 µm×4.6 mm×100 mm; Chiral Technology Korea, Daejeon, Korea) at wavelengths of excitation 338 nm and emission 425 nm.

Statistical analysis
--------------------

All results expressed as mean±standard deviation (SD) and analyzed by one-way analysis of variance (ANOVA) followed by Newman-Keuls multiple range test (parametric). The acceptable level of significance was established at *P*\<0.05

Results
=======

Changes in body weight, water and food consumption after final administration of streptozotocin
-----------------------------------------------------------------------------------------------

In mice treated with streptozotocin, the changes of body weight showed no significant difference compared with those of respective vehicle-treated mice during experimental period ([Figure 1A](#F1){ref-type="fig"}). Significant increase in water intake were observed from 10 days after last dose of streptozotocin in C57BL/6NKorl and C57BL/6NB mice, and from 14 days in C57BL/6NA mice ([Figure 1B](#F1){ref-type="fig"}). Food consumption of mice were slightly increased in streptozotocin-treated mice compared with those of respective vehicle-treated mice ([Figure 1C](#F1){ref-type="fig"}).

Changes in serum glucose concentration and relative organ weight in streptozotocin-induced diabetic mice
--------------------------------------------------------------------------------------------------------

Mice with greater than 300 mg/dL of blood glucose levels were considered diabetic in streptozotocin-induced model \[[@B18]\]. As shown in [Figure 2A](#F2){ref-type="fig"}, serum glucose concentration of streptozotocin-treated mice was more than 300 mg/dL and it was successfully established in mice of all origins. The liver-to-body weight ratios ([Figure 2B](#F2){ref-type="fig"}) were significantly increased 29, 42, and 21% in streptozotocin-treated C57BL/6NKorl, C57BL/6NA, C57BL/6NB, respectively. The weight of the kidney ([Figure 2C](#F2){ref-type="fig"}) was not changed in the streptozotocin-treated mice.

Effect of streptozotocin on the activities of ALT and AST
---------------------------------------------------------

Serum activity of ALT ([Figure 3A](#F3){ref-type="fig"}) was significantly increased by the treatment of streptozotocin (C57BL/6NKorl, 1.74 fold; C57BL/6NA, 1.98 fold; C57BL/6NB, 1.60 fold). AST activity in serum showed slight increase with significance only in C57BL/6NA mice treated with streptozotocin ([Figure 3B](#F3){ref-type="fig"}). There was no difference among the source of mice in the activities of both ALT and AST, suggesting that streptozotocin treatment affects liver function of diabetic mice.

Changes in serum total cholesterol and HDL-, LDL-cholesterol in streptozotocin-induced diabetic mice
----------------------------------------------------------------------------------------------------

There was no significant change in serum total cholesterol ([Figure 4A](#F4){ref-type="fig"}) and HDL-cholesterol ([Figure 4B](#F4){ref-type="fig"}) by streptozotocin administration. LDL-cholesterol was slightly increased with significance only in C57BL/6NB mice (vehicle, 7.92±0.60 mg/dL; streptozotocin, 9.59±0.64 mg/dL) ([Figure 4C](#F4){ref-type="fig"}).

Changes in serum metabolites in streptozotocin-induced diabetic mice
--------------------------------------------------------------------

As shown [Figure 5](#F5){ref-type="fig"}, many kinds of metabolites in serum were changed by streptozotocin treatment. The concentration of aspartate, citrulline, methionine, serine, threonine, glutamate, taurine, lysine, glycine, and tryptophan were decreased in streptozotocin-induced diabetic mice. Whereas, phenylalanine, ornithine, leucine, valine, and isoleucine were increased in streptozotocin-induced diabetic mice. There was no changes in the serum levels of tyrosine, histidine, alanine, asparagine, and arginine streptozotocin treatment. The changed pattern of serum metabolites was no significant difference among the source of mice.

Discussion
==========

A number of animal models have been used to elucidate the pathophysiology of varying diseases and to provide insight into potential targets and approaches for therapeutic intervention. Although various alternatives to animal testing have been proposed to help overcome potential drawbacks related to animal experiments and avoid ethical issues, they are still considered critical to the drug development process for treating human diseases. In particular, the study of metabolic diseases (eg, diabetes and obesity), requires the use of animal models to monitor whole-body physiology \[[@B19]\]. One of the most widely used laboratory mouse strains in metabolic research is the inbred C57BL/6 mouse which is commonly referred to as "Black 6", "B6", or "C57 Black" \[[@B19][@B20][@B21]\]. Inbred stains including the C57BL6 mouse are commonly used for biomedical and behavioral experiments, and data resulting from these studies have contributed substantially to the field\'s understanding of complicated biological processes \[[@B22][@B23][@B24]\]. In accordance with this, NIFDS has established its own inbred line of C57BL6/N named "C57BL6/NKorl" in the Guidelines for Nomenclature of Mouse Strains and been providing the characteristic information for animal researchers \[[@B25]\].

A diabetogenic effect of streptozotocin was first reported by Junod et al. who found that its effect resulted from selective destruction of pancreatic islet β-cells \[[@B26][@B27]\]. Several animal species are sensitive to the cytotoxic effect of streptozotocin and it is currently most often used to induce diabetes in rats and mice \[[@B28]\]. Specifically, multiple, lose-dose treatments of streptozotocin is increasingly being used to produce type-1 diabetic animal models which closely mimic symptoms seen in humans. In this study, a type-1 diabetic model of mice was induced by chronic injection of low dose streptozotocin and the response of C57BL/6NKorl mice was characterized by changes in basic physiology and serum metabolites. Furthermore, it was compared with the response of other mice obtained from two different commercially available sources.

No significantly different responses between the streptozotocin-induced type-1 diabetic mouse models used in this study were observed. When comparing control and diabetic mice, increases in liver weight and disturbances in serum amino acids levels of diabetic mice were most remarkable.

It has been suggested that increased triglyceride accumulation leads to an increase in the weight of livers from diabetic mouse model organisms because of the increased import of fatty acids into the liver induced by hypoinsulinemia and the low excretion of lipoprotein from the liver due to deficiency in the synthesis of apolipoprotein B \[[@B29][@B30][@B31][@B32]\]. In agreement with these reports, an important physiological change in this study is a significant increase in liver weight of streptozotocin-induced diabetic mice. This change is accompanied by increased activities of both ALT and AST suggesting that type-1 diabetes may induce abnormal liver functions.

Insulin leads to a decrease in serum amino acid levels through the stimulus of protein synthesis and the inhibition of proteolysis, which would explain the negative correlation between insulin dosage and plasma level of the amino acids in patients with diabetes \[[@B33]\]. It has been experimentally proven that insulin deficiency causes functional changes in the liver and muscle, which subsequently inhibits protein synthesis and promotes protein degradation. Interestingly, evidence is accumulating that there is a positive association between type-2 diabetes and circulating concentrations of BCAAs (eg, valine, leucine, isoleucine) \[[@B34][@B35][@B36]\]. Of note, the serum levels of many amino acids in the type-1 diabetic mice used in this study were decreased, but the serum concentration of BCAA was increased, which is similar to that observed in type-2 diabetes. Although the relationship between type-1 diabetes and BCAA has not been elucidated in this study, the results revealing a characteristic increase in diabetic mice of all origin are considered to be worthy of further study.

In conclusion, the responses of C57BL/6NKorl mice following streptozotocin treatment (eg, physiological, biochemical, metabolic) are not significantly different among mice of different orgins. Thus, our results suggest the usefulness of C57BL/6NKorl mice in preclinical testing of antidiabetic substances and those aiming to better elucidate the mechanisms of type-1 diabetes progression in humans.
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![Changes of (A) serum glucose level, and relative ratio of (B) liver-to-body and (C) kidney-to-body weight in streptozotocin-treated mice. Mice were given daily intraperitoneal injection with vehicle or 50 mg/kg body weight of streptozotocin (STZ) for 5 days. Changes were examined 4 weeks after final administration. ^\*\*\*^Significantly different from the corresponding vehicle-treated mice (ANOVA followed by Newman-Keuls multiple range test, *P*\<0.001, respectively).](lar-34-232-g002){#F2}
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